LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE; NEVIRAPINE
Pre-Launchlamivudine; tenofovir disoproxil fumarate; nevirapine
NDAORALTABLET
Lifecycle
Pre-Launch
Data completeness
0/8 — Limited
Drug data last refreshed 16h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
This is a fixed-dose combination tablet containing lamivudine, tenofovir disoproxil fumarate, and nevirapine—three nucleoside/nucleotide reverse transcriptase inhibitors and a non-nucleoside reverse transcriptase inhibitor used to treat HIV-1 infection. The combination works by inhibiting viral reverse transcriptase, reducing viral replication and slowing disease progression. This oral tablet formulation simplifies HIV treatment regimens by combining three active agents into a single dosing unit.
Pre-Launch
Pre-launch stage indicates early-stage commercial infrastructure building; limited team size but growing as regulatory milestones approach.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Joining the Hetero team on this product offers exposure to generic entry strategy, regulatory approval processes, and market access in high-burden HIV regions. Pre-launch stage creates early-career opportunities to shape commercial strategy and build market presence from launch.
Regulatory Affairs SpecialistCommercial Operations Manager
Worked on LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE; NEVIRAPINE at Hetero? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.